The MEDI ETF is an actively managed ETF that uses the Russell 3000 Growth Healthcare Index as its benchmark and selects companies in the healthcare industry that can be expected to benefit from long-term growth and innovation.

It suits long-term investors who want to focus on healthcare growth themes and rely on the management team's company selection rather than index tracking.

It is an ETF run by Harbor Capital using an active (actively managed) approach.

The fund mainly holds common and preferred shares of companies involved in the research, development, production, and distribution of healthcare products and services, and it builds its portfolio by considering quality, business differentiation, and valuation discipline together.

• Focus on healthcare growth and innovation themes
• Reflects both quality and valuation criteria

Assets under management (AUM) stand at $45.9M, and the expense ratio is 0.80% per year.

The MEDI ETF is a micro-cap-sized active healthcare ETF, so investors should check its trading conditions and fee burden alongside those of similar products.

The performance of the MEDI ETF can be affected by overall investor sentiment toward healthcare growth stocks, expectations for new drug development, the regulatory environment, and the earnings and clinical trial results of its major holdings. Even when following a long-term growth theme, price swings driven by individual stock news can be large.

Fund flows into the healthcare sector can be sensitive to interest rates, policy direction, discussions on drug pricing and insurance reimbursement, and clinical and approval news. Given its micro-cap size and concentrated composition, shifts in investor trading demand can affect trading conditions for the MEDI ETF.

Its approach of selecting innovative healthcare companies is a strength, but investors should also consider its non-diversified structure and the regulatory and development risks inherent to the industry.

The BBH ETF leans toward biotechnology, while the IDNA ETF emphasizes genomics and immunology-related themes. The GDOC ETF aims to select future healthcare companies, the MEDX ETF aims to provide access to the medical field, and the JDOC ETF takes an approach centered on healthcare leaders. The products in this comparison table differ in fee burden, asset size, and specific themes, so when comparing them with the concentrated active approach of the MEDI ETF, investors should check their target exposure and trading conditions.

When considering the MEDI ETF, investors should look beyond expectations for the healthcare growth theme and also check whether its active selection criteria, non-diversified structure, trading conditions, and distribution policy fit their own investment horizon and goals.

The healthcare industry can be affected by approvals, drug pricing, patents, R&D, changes in reimbursement systems, and competition. Because the MEDI ETF has a non-diversified structure, weakness in a few companies or a specific policy change can cause larger swings in net asset value and market price, and when it holds overseas securities, currency and country risks can be added.

The MEDI ETF is a product that explores long-term growth opportunities arising from healthcare innovation and the shift toward value-based care. However, because individual company selection and industry policy variables have a large influence, it is advisable to check costs, trading conditions, and concentration risk before approaching it in line with your own healthcare exposure goals.